Safety Plan for (ESAs) Used to Treat Chemotherapy-Related Anemia

One of the more common side effects of chemotherapy is anemia, or the lack of hemoglobin (red blood cells). Severe anemia is dangerous and will require the suspension of the use of chemotherapy as well as immediate treatment. In light of this the U.S. Food and Drug Administration (FDA) has required that Amgen Inc. developed [...]

A Common Advanced Prostate Cancer Emergency – Spinal Cord Compression

Spinal cord compression is not an uncommon occurrence in men with advanced prostate cancer. Bones are the most common target of advanced prostate cancer, including the spine. Sadly, there is often a delay in diagnosing spinal cord compression resulting from prostate cancer. These delays in diagnosis can influence the eventual functional outcome. Oncologists, primary care [...]

Coming in Early 2013 – A Genetic Test to Predict Which Prostate Cancers Need treatment and Which can be Subject to Active Surveillance

Genomic Health, Inc. has announced they have had positive results from a large clinical validation study of a biopsy-based prostate cancer test designed to predict adverse pathology in men with early prostate cancer. The study, performed in collaboration with prostate cancer researchers at the University of California, San Francisco (UCSF), met its primary endpoint by [...]

Can Tamoxifen Manage Breast Events Induced by Non-Steroidal Antiandrogens in Men with Advanced Prostate Cancer?

Many of us who are fighting advanced prostate cancer struggle with the perplexing side effects of non-steroidal antiandrogens (like Casodex). These side effects include gynecomastia (breast enlargement) and breast pain. In most cases as we use these drugs our breasts grow, become very sensitive and/or painful. In my case my breasts have grown to the [...]

Survival Advantage of Abiraterone Acetate (Zytiga) in Men with Castrate Resistant Metastatic Advanced Prostate Cancer

We all know that abiraterone acetate (Zytiga) plus prednisone provides a survival advantage for men with castrate resistant advanced prostate cancer (mCRPC) who have had prior treatment with a taxane based chemotherapy. New information has shown that abiraterone acetate offers a somewhat longer overall survival benefit than the data originally presented when the trial halted [...]

Go to Top